Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.62 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644969 | 1.00 | MAOA (0.62) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL17099397 | 0.91 | MAOA (0.54) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL30631693 | 0.88 | SRC (0.60) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL6849018 | 0.88 | SRC (0.60) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL1071646 | 0.87 | MAOA (0.62) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL30644950 | 0.87 | MAOA (0.62) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL260401 | 0.87 | ALDH1A1 (0.61) | MAOAMAOBALDH1A1TDP1HTT | |
| SCHEMBL6852137 | 0.86 | SRC (0.58) | MAOAMAOBALDH1A1TDP1SRC | |
| Benzene SCHEMBL17267850 | 0.84 | MAOA (0.58) | MAOAMAOBALDH1A1TDP1SRC | |
| SCHEMBL6856729 | 0.84 | SRC (0.56) | MAOAMAOBALDH1A1TDP1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615515-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-110914241-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110914241-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3615515-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018209363-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180312498-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013111393-A1 | HAIR GROWING AGENT | 学校法人東海大学 (JP) | 2013-08-01 | — | — | WO | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | MAOA 1074/4885MAOB 1114/4885ALDH1A1 962/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | MAOA 1074/4885MAOB 1114/4885ALDH1A1 962/4885 |
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | ITGA4, ITGB3, ITGB5 | MAOA 2866/4885MAOB 3323/4885ALDH1A1 232/4885 |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB4 | MAOA 2922/4885MAOB 3438/4885ALDH1A1 141/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | MAOA 1303/4885MAOB 1202/4885ALDH1A1 1508/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | MAOA 1206/4885MAOB 1120/4885ALDH1A1 1597/4885 |
| US-20180312498-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB5 | MAOA 2866/4885MAOB 3323/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.